Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INTROPIN vs LEUKINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dopamine is a direct agonist at dopamine (D1 and D2) and beta-1 adrenergic receptors, and at higher doses, alpha-1 adrenergic receptors. It also causes release of norepinephrine from sympathetic nerve terminals.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates proliferation, differentiation, and functional activity of neutrophils, monocytes, macrophages, and dendritic cells.
Hemodynamic support in cardiogenic shock,Hypotension not due to hypovolemia,Adjunct in cardiopulmonary resuscitation,Off-label: Bradycardia unresponsive to atropine
Myeloid reconstitution after autologous bone marrow transplantation,Mobilization of peripheral blood progenitor cells for collection,Post-chemotherapy neutropenia in non-myeloid malignancies,Treatment of severe chronic neutropenia (orphan designation),Off-label: treatment of acute radiation syndrome,Off-label: prevention of chemotherapy-induced febrile neutropenia
2-20 mcg/kg/min continuous IV infusion, titrated to achieve desired hemodynamic response. Typical initial dose: 5 mcg/kg/min.
250 mcg/m2/day IV over 2 hours on days 1-21 of a 28-day cycle for AML; 250 mcg/m2/day SC daily for 21 days for hematopoietic reconstitution after BMT; 250 mcg/m2/day SC daily for 10 days for mobilization of peripheral blood progenitor cells; 5 mcg/kg/day SC for 14 days for neutropenia due to ganciclovir in CMV retinitis.
Approximately 2 minutes. Short half-life allows rapid titration by intravenous infusion; effects cease within 5-10 minutes of discontinuation.
Terminal half-life: approximately 2.6 hours (range 1.3-4.5 hours) after subcutaneous administration; its short half-life requires daily dosing for sustained hematopoietic effect.
Metabolized in the liver, kidney, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) to inactive metabolites.
Primarily cleared by receptor-mediated internalization and degradation; not extensively metabolized by hepatic enzymes.
Primarily renal: 80% as unchanged drug and 20% as inactive metabolites (normetanephrine, homovanillic acid). Biliary/fecal excretion is negligible (<2%).
Renal: <5% unchanged; hepatically metabolized, with metabolites and parent drug eliminated primarily via biliary/fecal route (estimated >90% in animal studies).
25%, primarily to albumin.
Approximately 50-75% bound; primary binding proteins albumin and alpha-1-acid glycoprotein.
0.2 L/kg (0.16-0.24 L/kg). Small Vd indicates limited extravascular distribution; compatible with rapid onset and offset.
Volume of distribution: approximately 1.0-1.5 L/kg; distributed widely into tissues including bone marrow.
Oral: less than 5% due to extensive first-pass metabolism (MAO and COMT). Intramuscular: variable but limited due to peripheral vasoconstriction; not recommended.
Subcutaneous: approximately 50%; bioavailability after intramuscular administration has not been established.
No specific GFR-based dose adjustment required; monitor for renal perfusion adequacy and adjust based on clinical response.
No specific dose adjustment provided; use with caution in severe renal impairment (Cr Cl < 30 m L/min) due to potential accumulation.
No specific Child-Pugh-based adjustment; use with caution in severe hepatic impairment due to altered metabolism.
No specific dose adjustment provided; monitor hepatic function in patients with preexisting hepatic impairment.
0.5-20 mcg/kg/min continuous IV infusion; typical initial dose 2-5 mcg/kg/min, titrated to effect.
Safety and efficacy not established in pediatric patients; no specific dosing guidelines.
Start at lower end of dosing range (2-5 mcg/kg/min) due to increased sensitivity and comorbid conditions; titrate cautiously.
No specific dose adjustment recommended; monitor closely for adverse effects.
None
WARNING: Risk of respiratory distress syndrome, capillary leak syndrome, and fluid retention; increased risk of death in patients receiving concurrent chemotherapy or radiation therapy for non-myeloid malignancies.
Can cause ectopic heartbeats, tachycardia, angina, palpitations, vasoconstriction, and hypertension,May increase myocardial oxygen demand,Risk of tissue necrosis with extravasation,Use with caution in patients with occlusive vascular disease,Hypovolemia should be corrected before administration
Fluid retention and capillary leak syndrome,Respiratory symptoms: dyspnea, pleural effusion,Supraventricular arrhythmias,Bone pain,Allergic reactions,Increased risk of progression of myelodysplasia or leukemia,Monitor for blasts in peripheral blood
Pheochromocytoma,Uncorrected tachyarrhythmias,Hypersensitivity to sulfites (if formulation contains sulfites),Ventricular fibrillation
Hypersensitivity to GM-CSF or any component,Concurrent chemotherapy or radiation therapy to the bone marrow (in the setting of bone marrow transplantation),Leukemic blasts in blood or bone marrow (>10%)
No significant food interactions. However, patients on INTROPIN may have underlying conditions requiring dietary modifications (e.g., low sodium for hypertension). Avoid tyramine-rich foods if also taking MAOIs, though not a direct interaction with dopamine itself.
No known food interactions. No dietary restrictions required.
Pregnancy Category C. In first trimester, animal studies show fetal abnormalities (e.g., skeletal and visceral malformations) at high doses. Second and third trimesters: risk of reduced uteroplacental blood flow and fetal hypoxia due to vasoconstriction; may induce preterm labor.
LEUKINE (sargramostim) is a recombinant granulocyte-macrophage colony-stimulating factor. No adequate and well-controlled studies in pregnant women. In animal studies, no evidence of fetal harm was observed at doses up to 6 mg/kg/day in rats and rabbits. However, because animal reproduction studies are not always predictive of human response, LEUKINE should be used during pregnancy only if clearly needed. No known specific fetal risks by trimester, but theoretical risk due to potential for stimulating growth of hematopoietic cells in the fetus.
Excreted in breast milk in low concentrations; M/P ratio unknown. Potential for cardiovascular effects in infant; weigh benefits against risks.
It is not known whether LEUKINE is excreted into human milk. Many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from LEUKINE, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. No M/P ratio available.
No specific dose adjustment required; start at low doses and titrate to effect due to altered hemodynamics and increased plasma volume in pregnancy.
No specific pharmacokinetic studies in pregnancy. Pregnancy may alter volume of distribution and clearance, but no recommended dose adjustments have been established. Use standard weight-based dosing (250 mcg/m2/day) based on clinical indication, with close monitoring of therapeutic response and adverse effects. No dose adjustment is recommended solely due to pregnancy status.
INTROPIN (dopamine) is a catecholamine with dose-dependent effects: low dose (1-5 mcg/kg/min) stimulates D1 receptors causing renal vasodilation; intermediate dose (5-10 mcg/kg/min) activates β1 receptors increasing cardiac contractility and heart rate; high dose (>10 mcg/kg/min) stimulates α1 receptors leading to vasoconstriction. Monitor for extravasation as it can cause tissue necrosis; treat with phentolamine infiltration. Taper infusion gradually to avoid hypotension. Contraindicated in pheochromocytoma and uncorrected tachyarrhythmias.
Monitor for fluid retention and capillary leak syndrome. Obtain CBC with differential at baseline and twice weekly during therapy. Do not administer within 24 hours before or after chemotherapy. Reconstitute with 1 m L sterile water for injection; do not shake. Store reconstituted solution at 2-8°C and use within 6 hours.
This medication is given intravenously and requires continuous monitoring in a hospital setting.,Report any pain, burning, or swelling at the IV site immediately.,You may experience increased heart rate, chest pain, or shortness of breath; notify staff promptly.,Inform your healthcare provider if you have a history of irregular heartbeat, high blood pressure, or thyroid disease.,Do not stop or change the infusion rate; it is controlled by medical staff.
Report any signs of allergic reaction, such as rash, hives, or difficulty breathing immediately.,Notify your healthcare provider if you experience swelling, rapid weight gain, or shortness of breath.,Keep all appointments for blood tests to monitor your white blood cell counts.,Do not receive this medication within 24 hours before or after chemotherapy.,Store the medication in the refrigerator; do not freeze. Discard any unused portion after 6 hours.
No interactions on record
No interactions on record
Common clinical questions about INTROPIN vs LEUKINE, answered by our medical review team.
INTROPIN is a Catecholamine Vasopressor that works by Dopamine is a direct agonist at dopamine (D1 and D2) and beta-1 adrenergic receptors, and at higher doses, alpha-1 adrenergic receptors. It also causes release of norepinephrine from sympathetic nerve terminals.. LEUKINE is a Immunostimulant (Colony-Stimulating Factor) that works by Granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates proliferation, differentiation, and functional activity of neutrophils, monocytes, macrophages, and dendritic cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INTROPIN and LEUKINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INTROPIN is: 2-20 mcg/kg/min continuous IV infusion, titrated to achieve desired hemodynamic response. Typical initial dose: 5 mcg/kg/min.. The standard adult dose of LEUKINE is: 250 mcg/m2/day IV over 2 hours on days 1-21 of a 28-day cycle for AML; 250 mcg/m2/day SC daily for 21 days for hematopoietic reconstitution after BMT; 250 mcg/m2/day SC daily for 10 days for mobilization of peripheral blood progenitor cells; 5 mcg/kg/day SC for 14 days for neutropenia due to ganciclovir in CMV retinitis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INTROPIN and LEUKINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INTROPIN is classified as Category C. Pregnancy Category C. In first trimester, animal studies show fetal abnormalities (e.g., skeletal and visceral malformations) at high doses. Second and third trimesters: risk of re. LEUKINE is classified as Category C. LEUKINE (sargramostim) is a recombinant granulocyte-macrophage colony-stimulating factor. No adequate and well-controlled studies in pregnant women. In animal studies, no evidence . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.